Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 126325-53-9 | MDL No. : | MFCD03095078 |
Formula : | C6H7BrN2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | KLVZEEUNGGOROA-UHFFFAOYSA-N |
M.W : | 187.04 | Pubchem ID : | 14418051 |
Synonyms : |
|
Num. heavy atoms : | 9 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.17 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 41.31 |
TPSA : | 38.91 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.3 cm/s |
Log Po/w (iLOGP) : | 1.63 |
Log Po/w (XLOGP3) : | 1.6 |
Log Po/w (WLOGP) : | 1.74 |
Log Po/w (MLOGP) : | 0.92 |
Log Po/w (SILICOS-IT) : | 1.78 |
Consensus Log Po/w : | 1.54 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.5 |
Solubility : | 0.59 mg/ml ; 0.00316 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.03 |
Solubility : | 1.75 mg/ml ; 0.00936 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -2.91 |
Solubility : | 0.232 mg/ml ; 0.00124 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.75 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
38% | Stage #1: With hydrogenchloride; sodium nitrite In water at -5 - 0℃; Stage #2: With hexafluorophosphoric acid In waterCooling Stage #3: at 100℃; for 0.166667 h; |
General procedure: 3-Amino-2-bromo-6-methylpyridine(7a) or4-amino-2-bromo-6-methylpyridine(7b) (25.20 g, 134.73 mmol) wasadded to a mixture of water (78.1 mL) and conc. HCl (12.8 mL, 350.30 mmol), andthen the mixture was cooled to 0 oC. To it, sodium nitrite (18.6 g,269.46 mmol) was added portionwise with stirring over a period of 20 min whilekeeping the reaction temperature between –5 oCand 0 oC. After 10 min, 65percent hexafluorophosphoric acidsolution (43.26 g, 296.41 mmol) was added dropwise with cooling, atwhich point a lot of precipitates were formed. The precipitates were collectedby filteration using a glass filter funnel, washed with cold water (2 × 50 mL) and diethyl ether (100 mL), and then dried in the air for 48 h.The solid was slowly heated to 100 oC (very exothermic), and a darkred oily material was formed after 10 min. The oil was basified with dilutedNaOH solution to pH~10 and extracted with CH2Cl2 (2 × 150 mL). The combined organic layer was dried over anhydrous Na2SO4,filtered, and evaporated to dryness under reduced pressure. The residue waspurified by MPLC on neutral alumina using hexane/EtOAc (10:1) as eluent to affordthe titled compounds. |
[ 83004-10-8 ]
2-Bromo-6-(bromomethyl)pyridine
Similarity: 0.89
[ 104829-98-3 ]
2-Bromo-4,6-dimethylpyridin-3-amine
Similarity: 0.87
[ 104829-98-3 ]
2-Bromo-4,6-dimethylpyridin-3-amine
Similarity: 0.87
[ 34552-14-2 ]
3-Amino-2-bromo-5-methylpyridine
Similarity: 0.79
[ 83004-10-8 ]
2-Bromo-6-(bromomethyl)pyridine
Similarity: 0.89
[ 104829-98-3 ]
2-Bromo-4,6-dimethylpyridin-3-amine
Similarity: 0.87